Compare · CHFS vs INMD
CHFS vs INMD
Side-by-side comparison of CHF Solutions, Inc. (CHFS) and InMode Ltd. (INMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHFS and INMD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- INMD carries a market cap of $3.41B.
- INMD has hit the wire 1 time in the past 4 weeks while CHFS has been quiet.
- INMD has more recent analyst coverage (20 ratings vs 0 for CHFS).
- Company
- CHF Solutions, Inc.
- InMode Ltd.
- Price
- -
- $14.40+0.14%
- Market cap
- -
- $3.41B
- 1M return
- -
- +4.80%
- 1Y return
- -
- +1.02%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2019
- News (4w)
- 0
- 1
- Recent ratings
- 0
- 20
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Latest CHFS
- Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant
- Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021
- American Medical Association Issues New CPT Code for Nuwellis' Aquadex Ultrafiltration
- Nuwellis Announces New Appointments to Leadership Team
- Nationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. Collaboration
- ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure
- Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update
- Nuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021
- CHF Solutions Expands Commercial Focus, Changes Name to Nuwellis
- CHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
Latest INMD
- InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by new insider Mizrahy Moshe
- SEC Form 3 filed by new insider Kreindel Michael
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 6-K filed by InMode Ltd.